Clinical Characteristics and Prognosis of Systemic Anaplastic Large Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2022.04.020
- Author:
Juan FENG
1
;
Hai-Long TANG
1
;
Rui-Feng YUAN
1
;
Li XU
1
;
Yan-Hua ZHENG
1
;
Rong LIANG
1
;
Qing-Xian BAI
1
;
Tao ZHANG
1
;
Lan YANG
1
;
Hong-Tao GU
1
;
Guang-Xun GAO
2
Author Information
1. Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China.
2. Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China,E-mail: gaoguangxun@fmmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
anaplastic large cell lymphoma;
clinical characteristics;
prognosis
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Child;
Disease-Free Survival;
Female;
Humans;
Lymphoma, Large-Cell, Anaplastic/diagnosis*;
Male;
Middle Aged;
Prognosis;
Receptor Protein-Tyrosine Kinases;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2022;30(4):1109-1115
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical characteristics, treatment and prognosis of systemic anaplastic large cell lymphoma(sALCL).
METHODS:The clinical data of 90 cases with sALCL treated in the Department of Hematology of the Affiliated Xijing Hospital of Air Force Medical University from November 2018 to October 2021 were retrospectively analyzed. The clinical features, treatment and prognosis were summarized and the prognostic factors were investigated.
RESULTS:There were 58 males and 32 females, with a median age of 32 (12-73) years old. 69 (76.7%) patients had Ann Arbor stage Ⅲ-Ⅳ disease and half of the patients had extranodal infiltration. The median age was 27(12-72) years of the 60 ALK+ patients while 53(15-73) years of the 30 ALK- patients, and it was significantly different in the age of onset between the two group(P<0.01). 88 patients received first line chemotherapy, and 50(568%) cases achieved complete remission(CR). IPI score≥3 was an independent risk factor for CR. The median progressive free survival(PFS) and overall survival(OS) of the patients were not reached. Multivariate analysis showed that no achievement of CR after first-line therapy was a significant prognostic factor influencing PFS and OS.
CONCLUSION:sALCL mainly occurs in males and most patients were in advanced stage. Half of the patients had extranodal involvement. The CR rate after first-line chemotherapy was 568%, and IPI score≥3 was a significant prognostic factor for CR. No achievement of CR after first-line therapy is poorly prognostic for PFS and OS.
